Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
Mariana Chavez Mac GregorJieling MiaoLajos PusztaiMatthew P GoetzPriya RastogiPatricia A GanzEleftherios P P MamounasSoonmyung PaikHanna BandosWajeeha RazaqAnne O'DeaVirginia G KaklamaniAndrea L M SilberLisa E FlaumEleni AndreopoulouAlbert G WendtJennifer F CarneyPriyanka SharmaJulie R GralowDanika L LewWilliam E BarlowGabriel N HortobagyiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
One year of adjuvant everolimus + ET did not improve overall outcomes. Subset analysis suggests mTOR inhibition as a possible target for patients who remain premenopausal after chemotherapy.
Keyphrases
- phase iii
- double blind
- early stage
- open label
- placebo controlled
- clinical trial
- phase ii
- study protocol
- sentinel lymph node
- cell proliferation
- postmenopausal women
- type diabetes
- breast cancer risk
- stem cells
- locally advanced
- adipose tissue
- mesenchymal stem cells
- neoadjuvant chemotherapy
- bone marrow
- metabolic syndrome
- cell therapy
- data analysis